Humanized Strategy

landingpage-ashu-2000054-ccr8-hu-icpmouse-1

Humanized CCR8 Protein Sequence

landingpage-ashu-2000054-ccr8-hu-icpmouse-2

Alignment of Human and Humanized CCR8 Protein

landingpage-ashu-2000054-ccr8-hu-icpmouse-3

Overall Proportions of Immune Cells in the Blood of Humanized CCR8 Mouse

landingpage-ashu-2000054-ccr8-hu-icpmouse-4

Overall Proportions of Immune Cells in the Blood of Humanized CCR8 Mouse

landingpage-ashu-2000054-ccr8-hu-icpmouse-5

Overall Proportions of Immune Cells in the Blood of Humanized CCR8 Mouse

landingpage-ashu-2000054-ccr8-hu-icpmouse-6

hCCR8 Expression Validation in Humanized CCR8

landingpage-ashu-2000054-ccr8-hu-icpmouse-7

Binding of Anti-hCCR8 to Spleen-derived T cells in Humanized CCR8 Mouse

landingpage-ashu-2000054-ccr8-hu-icpmouse-8

Binding of Anti-hCCR8 to Spleen-derived T cells in Humanized CCR8 Mouse

landingpage-ashu-2000054-hu-icpmouse-9

In vivo Validation of Humanized CCR8 Mice

landingpage-ashu-2000054-ccr8-hu-icpmouse-10

Figure 1. In vivo validation of humanized CCR8 mice. Humanized CCR8 mice were inoculated with MC38 colon cancer cells, and were randomly assigned into different groups when the tumors grew to a volume of 100 mm3. Human-specific, CCR8 antibody was given in divided doses every 2 to 3 days for three weeks (Data in partnership with collaborators).  

Size

Mouse

Reviews

There are no reviews yet.

Be the first to review “CCR8 (2)”